An introduction to phosphate binders for the treatment of hyperphosphatemia in patients with chronic kidney disease

Kidney International, Supplement

Volumn 68, Issue 96, 2005, Pages

  Friedman, Eli A ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Calcium acetate; Hyperparathyroidism; Hypocalcemia

Indexed keywords

2 OXOISOVALERIC ACID; ALGINIC ACID; ALUMINUM HYDROXIDE; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CITRATE CALCIUM; LANTHANUM CARBONATE; MAGNESIUM CARBONATE; MAGNESIUM HYDROXIDE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D; MINERAL; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D DERIVATIVE; PHOSPHATE;

BICARBONATE BLOOD LEVEL; BONE TURNOVER; CALCIUM ABSORPTION; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; DIARRHEA; DRUG COST; DRUG CYTOTOXICITY; DRUG SAFETY; DRUG TOLERABILITY; ELECTRON BEAM TOMOGRAPHY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERMAGNESEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; METABOLIC ACIDOSIS; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; BLOOD VESSEL CALCIFICATION; DOSE RESPONSE; DRUG ABSORPTION; GLOMERULUS FILTRATION; HEALTH PRACTITIONER; HYPERPARATHYROIDISM; KIDNEY FAILURE; NUTRITIONAL ASSESSMENT; PRACTICE GUIDELINE; RENAL OSTEODYSTROPHY; RISK FACTOR; BLOOD; CHRONIC DISEASE; KIDNEY DISEASE; REVIEW;

CHRONIC DISEASE; HUMANS; KIDNEY DISEASES; PHOSPHATES;

EID: 26044437935     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00448.x     Document Type: Conference Paper

References (37)

1. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): State-specific trends in chronic kidney failure - United States, 1990-2001. MMWR Morb Mortal Wkly Rep 53:918-920, 2004
2. MASSRY S: K/DOQI guidelines released on bone metabolism and disease in CKD. Nephrol News Issues 17:38-41, 44, 2003
3. US RENAL DATA SYSTEM: USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004
4. BLOCK GA: Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients. Clin Nephrol 54:318-324, 2000
5. BLOCK GA, PORT FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 35:1226-1237, 2000
6. MARTINEZ I, SARACHO R, MONTENEGRO J, LLACH F: A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 11(Suppl 3):22-28, 1996
7. PAVLOVIC D, BRZAC HT: Prevention and treatment of secondary hyperparathyroidism: Still a challenge for the nephrologist? Nephrol Dial Transplant 18(Suppl 5):v45-v46, 2003
8. MALLUCHE HH, MONIER-FAUGERE MC: Understanding and managing hyperphosphatemia in patients with chronic renal disease. Clin Nephrol 52:267-277, 1999
9. HANLEY DA, SHERWOOD LM: Secondary hyperparathyroidism in chronic renal failure. Pathophysiology and treatment. Med Clin North Am 62:1319-1339, 1978
10. SALUSKY IB, GOODMAN WG: Cardiovascular calcification in end-stage renal disease. Nephrol Dial Transplant 17:336-339, 2002
11. EMMETT M: A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. Kidney Int (Suppl 90):S25-S32, 2004
12. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617, 1998
13. GOODMAN WG: Recent developments in the management of secondary hyperparathyroidism. Kidney Int 59:1187-1201, 2001
14. STEDDON SJ, SCHROEDER NJ, CUNNINGHAM J: Vitamin D analogues: How do they differ and what is their clinical role? Nephrol Dial Transplant 16:1965-1967, 2001
15. DRUEKE TB: Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis. Nephrol Dial Transplant 17(Suppl 11):20-22, 2002
16. QUARLES LD, SHERRARD DJ, ADLER S, et al: The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14:575-583, 2003
17. MALLUCHE HH, MAWAD H: Management of hyperphosphataemia of chronic kidney disease: Lessons from the past and future directions. Nephrol Dial Transplant 17:1170-1175, 2002
18. COLADONATO JA, SZCZECH LA, FRIEDMAN EA, OWEN WF, JR.: Does calcium kill ESRD patients - The skeptic's perspective. Nephrol Dial Transplant 17:229-232, 2002
19. US RENAL DATA SYSTEM: USRDS 1997 Annual Data Report, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1997
20. BRAUN J, OLDENDORF M, MOSHAGE W, et al: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27:394-401, 1996
21. MERIC F, YAP P, BIA MJ: Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. Am J Kidney Dis 16:459-464, 1990
22. QUNIBI WY, NOLAN CR: Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: results of the CARE study. Kidney Int (Suppl 90):S33-S38, 2004
23. KUZELA DC, HUFFER WE, CONGER JD, et al: Soft tissue calcification in chronic dialysis patients. Am J Pathol 86:403-424, 1977
24. CHERTOW GM, BURKE SK, RAGGI P, Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002
25. CANAVESE C, BERGAMO D, DIB H, et al: Calcium on trial: Beyond a reasonable doubt? Kidney Int 63:381-382, 2003
26. FOURNIER A, BENYAHIA M, CLAUDIA CP, SADEK T: Calcium on trial: Beyond a reasonable doubt? Kidney Int 63:382-383, 2003
27. INDRIDASON OS, QUARLES LD: Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int 57:282-292, 2000
28. CLEVELAND M: Calcium on trial: Beyond a reasonable doubt? Kidney Int 63:383, 2003
29. MAI ML, EMMETT M, SHEIKH MS, et al: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 36:690-695, 1989
30. NOLAN CR, QUNIBI WY: Calcium on trial: Beyond a reasonable doubt? Kidney Int 63:383-384, 2003
31. FINN WF, JOY MS, HLADIK G, LANTHANUM STUDY GROUP: Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 62:193-201, 2004
32. JOY MS, FINN WF, LAM-302 STUDY GROUP: Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 42:96-107, 2003
33. BEHETS GJ, VERBERCKMOES SC, HAESE PC, DE BROE ME: Lanthanum carbonate: A new phosphate binder. Curr Opin Nephrol Hypertens 13:403-409, 2004
34. NOLAN CR, QUNIBI WY: Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients. Curr Opin Nephrol Hypertens 12:373-379, 2003
35. QUNIBI WY, HOOTKINS RE, MCDOWELL LL, et al: Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 65:1914-1926, 2004
36. CHERTOW GM, DILLON M, BURKE SK, et al: A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 51:18-26, 1999
37. BREZINA B, QUNIBI WY, NOLAN CR: Acid loading during treatment with sevelamer hydrochloride: Mechanisms and clinical implications. Kidney Int (Suppl 90):S39-S45, 2004